vaccin
base
attenu
viral
vector
eg
poxvirus
adenoviru
highli
immunogen
rel
inexpens
produc
deliv
multipl
rout
advantag
acceler
develop
virusvector
vaccin
especi
concern
emerg
infecti
diseas
avian
influenza
multidrug
resist
tuberculosi
increas
howev
preexist
antivector
immun
significantli
impair
abil
rais
immun
respons
vaccin
preimmun
host
suggest
advantag
priorit
develop
viral
vaccin
vector
preexist
immun
rare
human
popul
vaccin
vector
base
recombin
vesicular
stomat
viru
rvsv
highli
immunogen
protect
small
anim
nonhuman
primat
rang
infecti
diseas
vsv
also
potent
oncolyt
agent
shown
superior
nine
virus
test
multifoc
glioma
cancer
natur
infect
human
vsv
extrem
uncommon
therefor
preexist
immun
rvsv
vector
almost
nonexist
despit
advantag
develop
rvsv
human
clinic
use
continu
delay
concern
vectorassoci
patholog
small
laboratori
anim
immun
rvsv
vaccin
display
clinic
sign
acut
ill
lose
preimmun
bodi
weight
first
four
day
immun
although
anim
recov
undesir
side
effect
would
unaccept
human
vaccine
weight
loss
less
pronounc
nonhuman
primat
immun
rvsv
one
human
date
therapeut
immun
singl
cycl
nonrepl
experiment
rvsv
vaccin
ebola
viru
develop
high
fever
transient
viremia
first
hour
vector
administr
result
demonstr
even
singl
cycl
vector
induc
signific
advers
side
effect
suggest
altern
strategi
reduc
residu
viral
vector
reactogen
requir
rvsvbase
vaccin
move
forward
clinic
use
import
identifi
way
elimin
rvsv
vectorassoci
patholog
time
compromis
vector
immunogen
oncolyt
properti
shown
previous
produc
respons
intranas
immun
rvsv
vaccin
vector
contribut
factor
respons
rapid
weight
loss
rvsv
immun
studi
defici
mice
partial
protect
acut
patholog
vsv
challeng
requir
gener
humor
immun
respons
rvsv
undertook
present
studi
expand
observ
focus
import
address
intramuscular
immun
like
rout
administr
rvsv
vector
human
mice
immun
recombin
vsv
rvsv
vaccin
vector
lose
weight
rapidli
immun
weight
loss
usual
maxim
second
day
immun
anim
recov
weight
return
normal
five
seven
day
immun
proinflammatori
cytokin
caus
acut
weight
loss
fever
mice
human
stimul
product
proinflammatori
mediat
prostaglandin
determin
whether
contribut
induct
acut
patholog
administr
rvsv
vaccin
vector
immun
group
wild
type
wt
n
receptor
defici
n
mice
singl
intramuscular
inject
pfu
live
replicationcompet
rvsv
anim
surviv
immun
wild
type
mice
lost
approxim
preimmun
bodi
weight
first
day
immun
figur
fulli
regain
preimmun
weight
eight
day
immun
contrast
mice
minim
patholog
lose
small
amount
weight
first
day
immun
return
start
weight
second
day
immun
mice
lost
significantli
less
weight
wild
type
control
anim
challeng
p
day
challeng
mannwhitney
test
mice
defici
respond
result
demonstr
either
bind
contribut
acut
patholog
rvsv
immun
regard
proinflammatori
cytokin
rather
commonli
associ
symptom
weight
loss
fever
induc
infect
live
viru
immun
stimulu
determin
whether
intramuscular
immun
vsv
vaccin
vector
induc
product
vivo
challeng
wild
type
mice
rvsv
use
elisa
quantit
amount
produc
local
inject
site
drain
lymph
node
system
blood
shown
figur
mice
immun
intramuscularli
rvsv
accumul
blood
quadricep
muscl
poplit
lymph
node
drain
quadricep
hour
immun
vsv
rwt
result
confirm
produc
vivo
local
system
intramuscular
rvsv
challeng
consist
result
poeck
et
al
found
wildtyp
mice
inject
intraven
rvsv
detect
level
serum
six
hour
challeng
result
also
consist
hypothesi
caus
acut
patholog
occur
immun
rvsv
vaccin
vector
suggest
reduc
product
rvsv
immun
might
correspondingli
reduc
reactogen
undesir
side
effect
vaccin
caus
deleteri
effect
fever
anorexia
also
shown
contribut
posit
gener
adapt
immun
respons
induc
live
viru
infect
role
control
vsv
replic
examin
previous
report
describ
role
control
virus
vivo
agreement
ultim
goal
abl
gener
less
reactogen
rvsv
vector
attenu
host
inflammatori
respons
import
determin
whether
requir
control
vaccin
vector
replic
gener
humor
cellular
immun
respons
gener
protect
rechalleng
investig
question
intramuscularli
immun
mice
defici
receptor
pfu
rvsv
measur
viral
load
induct
antibodi
cell
respons
protect
rechalleng
shown
figur
viral
load
quadricep
muscl
inject
site
significantli
differ
wild
type
mice
n
per
group
hour
infect
peak
vsv
replic
vivo
also
viru
detect
blood
infect
anim
result
demonstr
requir
control
vsv
replic
vivo
shown
figur
serum
neutral
antibodi
titer
vsv
significantli
differ
n
per
group
per
timepoint
wild
type
mice
n
per
group
per
timepoint
time
immun
use
mhc
class
tetram
measur
cell
respons
immunodomin
kbrestrict
epitop
nrgyvyqglc
vsv
n
protein
mice
slightli
fewer
antivsv
n
specif
cell
blood
wild
type
anim
figur
day
immun
although
differ
statist
signific
day
immun
p
twotail
test
final
determin
whether
immun
respons
suffici
protect
wild
type
mice
rechalleng
rvsv
challeng
anim
intranas
pfu
rvsv
eight
week
primari
infect
shown
figur
preimmun
wild
type
preimmun
mice
fulli
protect
rechalleng
wild
type
anim
n
open
triangl
figur
lost
preinfect
bodi
weight
two
seven
anim
succumb
infect
togeth
result
indic
requir
either
control
rvsv
replic
vivo
gener
protect
antivsv
immun
respons
result
also
support
idea
suppress
product
respons
respons
rvsv
vector
administr
would
render
rvsv
vector
unsaf
nonimmunogen
ultim
goal
studi
devis
strategi
could
suppress
product
therebi
reduc
patholog
rvsv
vector
vivo
sought
determin
mechan
produc
respons
vsv
synthes
inact
precursor
molecul
must
cleav
either
intracellularli
endogen
proteas
extracellularli
matrix
metalloproteas
neutrophil
mast
cellassoci
proteas
becom
biolog
activ
shown
recent
murin
bone
marrow
deriv
dendrit
cell
bmdc
infect
vsv
vitro
produc
via
format
inflammasom
compos
rna
helicas
rigi
adaptor
molecul
asc
author
test
whether
rigi
asc
requir
produc
respons
vsv
vivo
use
ascdefici
mice
determin
effect
absenc
molecul
acut
patholog
rvsv
immun
practic
test
rigi
defici
mice
induct
rigi
defici
mice
produc
ifn
respons
vsv
therefor
rapidli
succumb
infect
challeng
ascdefici
mice
wild
type
mice
intramuscularli
pfu
rvsv
figur
measur
product
acut
patholog
immun
shown
figur
system
local
product
significantli
reduc
mice
rel
wild
type
control
mice
immun
parallel
consist
result
predict
induc
acut
weight
loss
rvsv
infect
n
mice
lost
slightli
less
weight
rvsv
challeng
wild
type
n
mice
infect
parallel
differ
reach
statist
signific
second
day
challeng
p
mann
whitney
test
figur
second
experi
replic
find
almost
exactli
mice
n
show
slightli
enhanc
protect
rel
wild
type
anim
n
figur
differ
weight
loss
wild
type
mice
small
highli
reproduc
mice
never
protect
extent
mice
confirm
observ
infect
three
group
parallel
pfu
rvsv
intramuscular
shown
figur
mice
n
lost
significantli
less
weight
wild
type
n
mice
day
challeng
p
via
one
way
anova
bonferroni
multipl
comparison
test
recov
preimmun
bodi
weight
quickli
either
wild
type
mice
differ
weight
loss
mice
signific
first
second
day
challeng
p
via
one
way
anova
bonferroni
multipl
comparison
test
similar
result
obtain
mice
mice
made
equival
humor
respons
slightli
reduc
cellular
respons
vsv
fulli
protect
high
dose
rechalleng
figur
taken
togeth
result
demonstr
product
vivo
intramuscular
rvsv
immun
occur
independ
inflammasom
adaptor
molecul
asc
asc
defici
mice
protect
fulli
acut
patholog
rvsv
immun
strategi
suppress
function
asc
would
predict
partial
complet
abrog
acut
patholog
rvsv
immun
similarli
immun
mice
defici
wild
type
mice
pfu
rvsv
defici
mice
significantli
reduc
level
rel
wild
type
mice
figur
measur
product
inject
site
drain
lymph
node
elisa
consist
data
defici
mice
immun
intramuscularli
pfu
rvsv
figur
n
per
group
partial
complet
protect
acut
weight
loss
figur
rel
wild
type
mice
n
differ
weight
loss
wild
type
mice
signific
day
challeng
p
mann
whitney
test
defici
mice
control
viral
replic
well
wild
type
mice
figur
n
per
group
signific
differ
viral
load
quadricep
muscl
infect
anim
hour
infect
mice
viru
recov
blood
infect
mice
defici
mice
made
robust
humor
figur
cellular
figur
respons
vsv
significantli
differ
wild
type
mice
undertook
studi
goal
determin
cytokin
induc
rvsv
contribut
acut
patholog
intramuscular
immun
import
vsv
highli
promis
vaccin
vector
oncolyt
agent
clinic
develop
lag
behind
live
virus
concern
vectorassoci
patholog
fever
myalgia
sick
respons
induc
mani
live
viral
bacteri
vaccin
vaccineinduc
side
effect
among
lead
reason
individu
elect
receiv
protect
vaccin
consist
result
obtain
mous
model
present
sever
recent
studi
correl
increas
level
proinflammatori
cytokin
induct
high
fever
advers
event
respons
live
viru
vaccin
human
identifi
genet
polymorph
gene
predispos
individu
sever
advers
event
receiv
live
viru
vaccin
reason
import
determin
way
proinflammatori
cytokin
contribut
reactogen
vsv
vector
particular
find
could
advanc
develop
vsvbase
therapeut
also
find
might
help
inform
develop
live
viru
vaccin
oncotherapi
previou
studi
vsv
vector
deliv
mice
intranas
show
intranas
immun
vsv
induc
proinflammatori
cytokin
product
directli
correl
weight
loss
acut
patholog
although
intranas
immun
mani
advantag
needl
free
deliveri
induct
mucos
immun
etc
signific
drawback
intranas
immun
rvsv
risk
neurotrop
spread
viru
vsv
instil
nose
rapidli
colon
olfactori
neuron
migrat
brain
neurovirul
vsv
vector
significantli
reduc
attenu
capac
vsv
vector
replic
even
remot
chanc
neurotrop
spread
like
prevent
use
intranas
rout
human
inocul
therefor
decid
determin
cytokin
respons
acut
patholog
intramuscular
immun
regard
safer
rout
administ
potenti
neurotrop
agent
show
mice
defici
receptor
significantli
protect
weight
loss
intramuscular
challeng
vsv
although
result
preclud
contribut
inflammatori
process
patholog
posit
identifi
import
target
intervent
receptor
bind
therefor
mice
protect
patholog
possibl
cytokin
contribut
vsvassoci
patholog
vivo
well
character
mediat
acut
inflammatori
respons
mice
human
name
induct
fever
cachexia
acut
phase
respons
upregul
inflammatori
mediat
respons
infecti
noninfecti
stimuli
review
commonli
associ
patholog
exampl
defici
mice
defici
mice
protect
fever
inject
turpentin
similarli
etiolog
agent
hereditari
period
fever
syndrom
autoinflammatori
diseas
human
commonli
associ
steril
inflamm
accompani
apoptot
cell
death
except
adenoviru
mediat
inflamm
associ
patholog
aris
viral
infect
reason
predict
primari
mediat
patholog
system
experi
requir
formal
exclud
role
establish
contribut
acut
patholog
intramuscular
vsv
inocul
import
question
pursu
whether
would
requir
control
vsv
replic
vivo
induct
immun
respons
vsv
vector
requir
control
viru
replic
gener
protect
immun
respons
would
suggest
engin
rvsv
vector
suppress
product
andor
signal
would
ration
approach
reduc
rvsv
associ
patholog
although
three
separ
report
describ
induct
respons
vsv
challeng
vivo
none
examin
whether
induc
contribut
posit
requir
gener
immun
respons
protect
viral
infect
model
investig
publish
report
agreement
exampl
schmitz
et
al
found
mice
infect
influenza
significantli
higher
rate
mortal
wild
type
control
anim
increas
mortal
correl
higher
viru
burden
mice
three
addit
report
examin
role
well
compon
inflammasom
control
influenza
infect
two
three
found
transient
elev
viral
load
mice
product
decreas
report
found
differ
viru
burden
similarli
one
three
report
found
reduct
correl
reduct
cellular
immun
respons
other
either
examin
immun
respons
find
correl
studi
found
mice
control
viral
load
well
wild
type
control
anim
viral
load
inject
site
significantli
differ
group
neither
group
detect
viremia
challeng
result
highlight
rel
safeti
intramuscular
immun
rout
equal
import
mice
challeng
vsv
made
robust
humor
cellular
respons
vsv
antigen
fulli
protect
high
dose
intranas
rechalleng
vsv
interestingli
observ
level
antivsv
cell
mice
mice
transient
significantli
decreas
consist
report
iwasaki
et
al
found
antiinfluenza
cell
respons
slightli
decreas
mice
reduc
level
product
studi
number
antivsv
specif
cell
significantli
lower
mice
day
infect
significantli
differ
either
day
infect
find
warrant
investig
followup
studi
focu
determin
whether
cell
prime
absenc
signal
function
differ
eg
cytotox
capac
acquisit
central
memori
phenotyp
prime
intact
anim
summari
result
support
idea
product
requir
either
control
vsv
replic
vivo
induct
protect
immun
respons
vsv
antigen
intramuscular
immun
rel
magnitud
immun
respons
foreign
antigen
express
vsv
gener
similar
rel
magnitud
immun
respons
vsv
antigen
predict
would
also
requir
induct
immun
respons
vaccin
antigen
express
vsv
nonetheless
determin
whether
import
respons
foreign
vaccin
antigen
express
rvsv
import
direct
studi
second
question
aris
result
vsvinduc
product
might
suppress
one
mean
suppress
biolog
respons
human
via
inject
recombin
receptor
antagonist
current
market
drug
anakinra
kineret
agent
effect
system
suppress
although
system
suppress
effect
treatment
condit
sever
rheumatoid
arthriti
exampl
system
suppress
also
carri
risk
enhanc
suscept
infect
therefor
decid
determin
whether
might
way
suppress
cell
directli
infect
vsv
within
focu
vsvinfect
cell
determin
appropri
target
molecul
effect
local
suppress
necessari
determin
mechan
produc
model
sever
year
ago
muruv
et
al
report
adenoviru
activ
human
monocyt
cell
produc
vitro
product
depend
upon
supplement
manuscript
author
report
infect
cell
vsv
induc
product
although
detail
method
studi
provid
contrast
two
recent
studi
report
vsvinfect
cell
produc
vitro
first
studi
poeck
et
al
found
vsv
induc
product
depend
upon
upon
contrast
rajan
et
al
found
vsv
mediat
induct
cell
depend
depend
like
discrep
report
due
subtl
differ
experiment
procedur
differ
outcom
report
group
highlight
complex
elucid
precis
mechan
vsv
may
induc
studi
found
vsv
induc
robust
product
vivo
still
produc
mice
lack
asc
one
caveat
find
elisa
assay
one
use
rigor
discrimin
detect
detect
cleav
activ
therefor
possibl
detect
mice
biolog
activ
precis
determin
amount
activ
present
mice
requir
develop
better
detect
reagent
despit
limit
result
support
model
multipl
pathway
matur
produc
vivo
respons
vsv
data
also
consist
idea
manner
matur
produc
via
may
vari
cell
induc
observ
mice
lack
asc
protect
acut
patholog
extent
mice
meant
vsv
vector
engin
suppress
compon
inflammasom
inflammasom
would
unlik
significantli
less
reactogen
parent
vector
hand
rvsv
design
suppress
biolog
respons
exampl
via
inclus
solubl
trap
via
inclus
solubl
receptor
antagonist
might
reduc
biolog
respons
vivo
therefor
less
reactogen
summari
shown
contribut
acut
patholog
intramuscular
immun
vsv
requir
control
viral
replic
induct
cellular
humor
immun
respons
develop
protect
immun
rechalleng
result
add
understand
role
promot
immun
viral
challeng
support
notion
requir
promot
adapt
immun
may
vari
accord
type
dose
pathogen
encount
well
rout
exposur
final
identifi
major
sourc
reactogen
rvsv
vaccin
abl
propos
novel
strategi
amelior
side
effect
without
compromis
immunogen
anim
studi
review
approv
duke
univers
institut
anim
care
use
committe
vesicular
stomat
viru
indiana
strain
origin
obtain
dr
john
rose
yale
univers
viru
propag
cell
atcc
titer
use
standard
plaqu
assay
eight
tenweekold
wildtyp
receptor
type
defici
strain
name
mice
obtain
jackson
laboratori
background
gener
provid
dr
fayyaz
sutterwala
dr
richard
flavel
mice
background
gener
provid
genentech
inc
san
francisco
ca
mice
obtain
commerci
hous
least
week
experi
initi
mice
hous
microisol
cage
biosafeti
level
anim
facil
viral
stock
dilut
appropri
titer
serumfre
dmem
intramuscular
immun
im
mice
inject
indic
amount
viru
es
total
volum
intranas
vaccin
mice
lightli
anesthet
isofluran
use
vapor
administ
indic
amount
viru
total
volum
institut
anim
care
use
committe
duke
univers
approv
anim
experi
mice
sacrif
via
anesthet
overdos
organ
remov
asept
dissect
organ
weigh
homogen
steril
buffer
buffer
per
g
organ
weight
homogen
titer
standard
plaqu
assay
cell
atcc
use
semisolid
overlay
detect
infecti
vsv
hour
overlay
remov
cell
layer
stain
crystal
violet
visual
plaqu
mice
bled
sacrif
via
anesthet
overdos
organ
remov
asept
organ
homogen
lymph
node
buffer
contain
mm
nacl
mm
triscl
ph
mm
edta
tritonx
proteas
inhibitor
cocktail
roch
serum
organ
homogen
supernat
assay
elisa
r
system
organ
amount
normal
amount
protein
sampl
determin
use
bicinchonin
acid
bca
protein
assay
thermo
scientif
blood
obtain
mice
day
vaccin
via
cheek
bleed
heat
inactiv
serum
dilut
serumfre
dmem
final
dilut
first
well
plate
day
sampl
day
sampl
subsequ
twofold
dilut
sampl
assay
duplic
pfu
rvsv
dilut
serumfre
dmem
ad
well
incub
one
hour
cell
atcc
dilut
fbsdmem
ad
well
plate
incub
three
day
cytopath
effect
observ
neutral
titer
defin
highest
dilut
serum
gave
neutral
rvsv
obtain
peripher
blood
lymphocyt
blood
collect
serum
free
medium
dmem
contain
heparin
blood
layer
onto
ficol
gradient
spun
lymphocyt
collect
interfac
cell
wash
resuspend
dmem
contain
fc
stain
perform
freshli
isol
lymphocyt
previous
describ
briefli
approxim
cell
ad
well
vbottom
plate
block
unconjug
streptavidin
molecular
probe
fc
block
pharmingen
min
room
temperatur
rt
follow
centrifug
lymphocyt
label
fitcconjug
antibodi
pharmingen
allophycocyaninconjug
antibodi
pharmingen
tetram
min
rt
tetram
peconjug
major
histocompat
complex
mhc
class
kb
tetram
nih
tetram
facil
contain
restrict
peptid
vsv
nrgyvyqglc
shaminocul
control
anim
use
determin
background
level
tetram
bind
background
routin
less
subtract
report
percentag
statist
comparison
made
use
graphpad
prism
softwar
result
consid
signific
p
